NEW YORK (GenomeWeb News) – Molecular diagnostics and cytology test developer Veracyte said this week that it has named Shelly Guyer to be its chief financial officer.
Guyer formerly was CFO and executive VP of finance and administration at iRhythm Technologies, and she was VP of business development and investor relations at the biotech firm Nuvelo. She also spent 17 years at JP Morgan Securities and its predecessor companies, where she led financing for large- and small-cap life sciences firms.
The South San Francisco-based firm has developed and is now offering its first product, the Afirma Thyroid FNA Analysis test for improving thyroid nodule diagnosis, through a global partnership with Genzyme.
Benitec Biopharma has appointed Kevin Buchi to its board of directors.
Buchi previously served as CEO of Cephalon prior to its acquisition by Teva Pharmaceutical in 2011.
He currently sits on the boards of Stemline Therapeutics, Forward Pharma, and Alexza Pharamceuticals.
Karolinska Development has nominated Bo Jesper Hansen to be chairman of its board.
The for-profit company seeks to move medical innovations toward commercialization, particularly through agreements with Karolinska Institute Innovations and Nordic universities. If approved, Hansen will succeed Hans Wigzell in the position in October. Wigzell will remain on the board as an ordinary member after Hansen assumes the chair.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.